Blood markers may predict arthritis drug success
NCT ID NCT03561649
First seen May 31, 2026
Summary
This study aimed to find blood markers that can predict whether the drug adalimumab will successfully treat ankylosing spondylitis after 6 months. Researchers analyzed blood samples from 50 adults starting adalimumab for the first time. The goal was to create an algorithm to help doctors identify which patients are most likely to benefit from the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH de Belfort
Belfort, 90016, France
-
CHRU de Clermont-Ferrand
Clermont-Ferrand, 63003, France
-
CHU de Besançon
Besançon, 25030, France
-
CHU de Grenoble
Échirolles, 38434, France
-
CHU de Saint-Etienne
Saint-Etienne, 42055, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.